Drug to treat agitation in Alzheimer’s patients approved in Canada

Health Canada has green lit a drug previously approved for schizophrenia and depression to treat symptoms of agitation in Alzheimer’s patients – a common symptom of the disease. Rexulti (brexpiprazole) oral tablets manufactured by Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. were issued a Notice of Compliance by the regulator, according to a company release Wednesday. This approval was given after three 12-week randomized, double-blind, placebo-controlled studies, the release said. Global's Katherine Ward explains. For more info, please go to https://globalnews.ca/news/10249782/alzheimers-agitation-symptoms-canada-drug-approval/ Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc Like Global News on Facebook HERE: http://bit.ly/255GMJQ Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB #Health #Alzheimers #Dementia